Literature DB >> 28270950

Trends of partial and radical nephrectomy in managing small renal masses.

Ibrahim Khalid Al Saidi1, Kholoud Saleh Alqasem1, Saeda Turki Gharaibeh1, Naim Z N Qamhia1, Ibrahim Abukhiran1, Ali Ahmad Al-Daghmin1.   

Abstract

OBJECTIVE: Use of partial nephrectomy (PN) for renal tumors appears to have relatively lower incidence rates in Jordan. We sought to characterize its trend at King Hussein Cancer Center for the last 10 years.
MATERIAL AND METHODS: A retrospective review of our renal cell cancer data was performed. We identified 169 patients who had undergone surgery for renal tumors measuring ≤7 cm between 2005 and 2015. We characterized tumor size, pathology, type of surgery and clinical outcomes. Factors associated with the use of PN were evaluated using univariable and multivariable logistic regression models.
RESULTS: Of the 169 patients, 34 (20%) and 135 (80%) had undergone partial and radical nephrectomy (RN) respectively for tumors ≤7 cm in diameter. Total number of 48 patients with tumors of ≤4 cm in diameter had undergone either PN (n=19; 40%) or RN (n=29; 60%). The frequency of PN procedures steadily increased over the years from 6% in 2005-2008, to 32% in 2013-2015, contrary to RN which was less frequently applied 94% in 2005-2008, and 68% in 2013-2015. In multivariable analysis, delayed surgery (p=0.01) and smaller tumor size (p=0.0005) were significant independent predictors of PN. During follow-up period, incidence of metastasis was lower in PN versus RN (13% and 32%, respectively, p=0.043). Local recurrence rates were not significantly different between PN (6.9%) and RN (7.2%) (p=0.99). The mean tumor sizes for patients who had undergone PN and RN were 4.1 and 5.5 cm respectively, (p<0.0001). The mean follow-up period for PN was 20 months, and for RN 33 months, (p=0.0225).
CONCLUSION: Partial nephrectomy for small renal tumors is relatively less frequently applied in Jordan, however an increase in its use has been observed over the years. Our data showed lower rates of distant metastasis and similar rates of local recurrence in favor of PN.

Entities:  

Keywords:  Current guidelines; partial nephrectomy; renal cell carcinoma; trends

Year:  2017        PMID: 28270950      PMCID: PMC5330267          DOI: 10.5152/tud.2016.33667

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  14 in total

1.  Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.

Authors:  William C Huang; Andrew S Levey; Angel M Serio; Mark Snyder; Andrew J Vickers; Ganesh V Raj; Peter T Scardino; Paul Russo
Journal:  Lancet Oncol       Date:  2006-09       Impact factor: 41.316

2.  Guideline for management of the clinical T1 renal mass.

Authors:  Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

3.  Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients.

Authors:  F Becker; S Siemer; U Humke; M Hack; M Ziegler; M Stöckle
Journal:  Eur Urol       Date:  2005-12-09       Impact factor: 20.096

4.  A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma.

Authors:  Sara Baillargeon-Gagné; Claudio Jeldres; Giovanni Lughezzani; Maxine Sun; Hendrik Isbarn; Umberto Capitanio; Shahrokh F Shariat; Maxime Crépel; Ahmed Alasker; Hugues Widmer; Philippe Arjane; Jean-Jacques Patard; Paul Perrotte; Francesco Montorsi; Markus Graefen; Pierre I Karakiewicz
Journal:  BJU Int       Date:  2010-02       Impact factor: 5.588

5.  The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth.

Authors:  Alexander Kutikov; Robert G Uzzo
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

6.  Renal and cardiovascular morbidity after partial or radical nephrectomy.

Authors:  David C Miller; Matthias Schonlau; Mark S Litwin; Julie Lai; Christopher S Saigal
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

7.  Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy.

Authors:  R Houston Thompson; Stephen A Boorjian; Christine M Lohse; Bradley C Leibovich; Eugene D Kwon; John C Cheville; Michael L Blute
Journal:  J Urol       Date:  2008-02       Impact factor: 7.450

8.  Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.

Authors:  Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

9.  Partial nephrectomy for small renal masses: an emerging quality of care concern?

Authors:  David C Miller; John M Hollingsworth; Khaled S Hafez; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

10.  Radical versus partial nephrectomy: effect on overall and noncancer mortality.

Authors:  Laurent Zini; Paul Perrotte; Umberto Capitanio; Claudio Jeldres; Shahrokh F Shariat; Elie Antebi; Fred Saad; Jean-Jacques Patard; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

View more
  2 in total

1.  Kidneys with small renal masses: Can they be utilized for kidney transplantation in the era of partial nephrectomy?

Authors:  Emre Arpalı; Bilal Günaydın; Turgay Turan; Turhan Çaşkurlu; Asıf Yıldırım; Burak Koçak
Journal:  Turk J Urol       Date:  2018-11

2.  Comparison of overall survival and unplanned hospital readmissions between partial and radical nephrectomy for cT1a and cT1b renal masses.

Authors:  Julio T Chong; David Paulucci; Marc Lubin; Alp Tuna Beksac; Greg Gin; John P Sfakianos; Ketan K Badani
Journal:  Ther Adv Urol       Date:  2018-11-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.